Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

In the Spotlight

Of Microbes and Microsatellites

Chloe E. Atreya and Alan P. Venook
Chloe E. Atreya
Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chloe.atreya@ucsf.edu
Alan P. Venook
Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6066.CIR-18-0567 Published November 2018
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

A ubiquitous oral cavity microbe, Fusobacterium nucleatum, is increasingly being implicated in colorectal cancer pathogenesis. An article in this issue elucidates the differential association of F. nucleatum with tumor-infiltrating lymphocytes depending on microsatellite instability status. Cancer Immunol Res; 6(11); 1290–1. ©2018 AACR.

See article by Hamada et al., p. 1327.

A human's intestines are sometimes dismissed as merely a conduit through which solid waste can be transported and expelled. In reality, the intestines represent a vital organ that plays a central physiologic role in functions ranging from digestion to maintenance of fluid balance to regulating parts of our immune system to hosting the huge community of microbiota called the microbiome.

To state the obvious, studying the microbiome is a daunting challenge. It is estimated that the number of microbiota is about 36 trillion. The diversity of species is staggering, and its members may change depending on the components of a recent meal or a dose of antibiotics. New molecular and biostatistical tools and the advances in immunotherapy have fueled the recent surge in interest in the microbiome—but where to start?

Since 2012, a group of coauthors has focused their efforts on dissecting the role of one bacterium, F. nucleatum, found to be enriched in colorectal carcinomas compared with matched normal colons (1). Mima and colleagues discovered that the proportion of F. nucleatum–high colorectal cancers gradually decreases along the continuum from the cecum to rectum (2), which may contribute to the explanation for the recent recognition that patients with advanced colorectal cancer originating in the proximal (right-sided) colon have a worse prognosis as compared with patients with tumors originating in the distal (left-sided) colon. Other factors are also operative, such as a gradient distribution of tumor mutations and patterns of gene expression, which may relate to distinct embryologic origins (right colon from the midgut; left colon from the hindgut). Nevertheless, F. nucleatum associates with poor prognosis right-sided and microsatellite instability (MSI)–high colorectal cancers. Remarkably, F. nucleatum was also observed to persist in distant metastatic lesions, and even through successive passages in patient-derived xenograft models (3).

Meanwhile, colorectal cancer has also gained notoriety in the immunotherapy space, albeit for its extraordinarily low responsiveness to checkpoint inhibitors. Even colorectal cancers with intermediate or moderately high tumor mutation burden are impervious to these treatments. The 5% of metastatic colorectal cancers that are MSI-high are the exception, with an objective response rate to pembrolizumab or nivolumab of ∼30%. Beyond MSI, biomarkers of nonresponse or response to checkpoint inhibitors have remained elusive. And this is where the next chapter of F. nucleatum research begins.

Here, Hamada and colleagues report that the presence F. nucleatum is positively correlated with tumor-infiltrating lymphocytes (TILs) in non–MSI-high tumors and inversely correlated with TILs in MSI-high tumors (4). In non–MSI-high cancers with fewer neoantigens, the proinflammatory effects of F. nucleatum appear to dominate, promoting a lymphocytic reaction. In MSI-high tumors with abundant neoantigens, F. nucleatum appears to suppress the adaptive immune response. Although not yet directly evaluated, the implication is that the presence of F. nucleatum may explain why some MSI-high colorectal cancers are able to evade immune-checkpoint blockade.

Such provocative findings will surely inspire further microbiome research, ranging from detailed mechanistic analyses to comprehensive sequencing-based surveys. Moreover, studies like this one are ushering in a new era of colorectal cancer clinical trials. In the near future, expect to see a proliferation of human trials involving antibiotics, probiotics, prebiotics, dietary modifications, and fecal microbiotica transplants. Although F. nucleatum cannot possibly tell the whole story, this work does give us a hopeful glimpse at a future where cost-efficient complementary approaches may yield effective prevention strategies, as well as tunable means to maximize efficacy and mitigate toxicity of immuno- and cancer-directed therapies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • ©2018 American Association for Cancer Research.

References

  1. 1.↵
    1. Kostic AD,
    2. Gevers D,
    3. Pedamallu CS,
    4. Michaud M,
    5. Duke F,
    6. Earl AM,
    7. et al.
    Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012;22:292–8.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Mima K,
    2. Cao Y,
    3. Chan AT,
    4. Qian ZR,
    5. Nowak JA,
    6. Masugi Y,
    7. et al.
    Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol 2016;7:e200.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Bullman S,
    2. Pedamallu CS,
    3. Sicinska E,
    4. Clancy TE,
    5. Zhang X,
    6. Cai D,
    7. et al.
    Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017;358:1443–8.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Hamada T,
    2. Zhang X,
    3. Mima K,
    4. Bullman S,
    5. Sukawa Y,
    6. Nowak JA,
    7. et al.
    Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol Res 2018;6:1327–36.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Immunology Research: 6 (11)
November 2018
Volume 6, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Of Microbes and Microsatellites
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Of Microbes and Microsatellites
Chloe E. Atreya and Alan P. Venook
Cancer Immunol Res November 1 2018 (6) (11) 1290-1291; DOI: 10.1158/2326-6066.CIR-18-0567

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Of Microbes and Microsatellites
Chloe E. Atreya and Alan P. Venook
Cancer Immunol Res November 1 2018 (6) (11) 1290-1291; DOI: 10.1158/2326-6066.CIR-18-0567
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • How to Reprogram Myeloma-Associated Macrophages: Target IKZF1
  • Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2
  • TGFβ: Protecting PD-1 from mRNA Decay
Show more In the Spotlight
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement